{"id":6961,"date":"1970-01-01T00:00:00","date_gmt":"1970-01-01T00:00:00","guid":{"rendered":"https:\/\/www.nicox.com\/nicox-finalise-lacquisition-deupharmed\/"},"modified":"1970-01-01T00:00:00","modified_gmt":"1970-01-01T00:00:00","slug":"nicox-finalise-lacquisition-deupharmed","status":"publish","type":"post","link":"https:\/\/www.nicox.com\/fr\/nicox-finalise-lacquisition-deupharmed\/","title":{"rendered":"Nicox finalise l\u2019acquisition d\u2019Eupharmed"},"content":{"rendered":"<p>\n Nicox S.A. (NYSE Euronext Paris : COX) annonce aujourd\u2019hui la r\u00e9alisation d\u00e9finitive de l\u2019acquisition de 100% du capital d\u2019Eupharmed, soci\u00e9t\u00e9 pharmaceutique italienne priv\u00e9e sp\u00e9cialis\u00e9e en ophtalmologie. Cette acquisition s\u2019inscrit dans la strat\u00e9gie de Nicox visant \u00e0 \u00e9tablir une infrastructure commerciale dans les cinq principaux march\u00e9s europ\u00e9ens et aux Etats-Unis et apporte \u00e0 Nicox une plate-forme de ventes et de marketing bien implant\u00e9e en Italie, de m\u00eame qu\u2019un vaste portefeuille de produits oculaires commercialis\u00e9s.<\/p>\n<p>\n Pour plus d\u2019informations, veuillez consulter les communiqu\u00e9s suivants :<\/p>\n<ul>\n<li>\n  Communiqu\u00e9 de presse du 26 novembre 2013&nbsp;: <a href=\"https:\/\/www.nicox.com\/assets\/files\/pr2013112600fr.pdf\">Nicox \u00e9tablit un r\u00e9seau commercial en Italie avec l\u2019acquisition d\u2019Eupharmed<\/a><\/li>\n<li>\n  Communiqu\u00e9 de presse du 5 d\u00e9cembre 2013 (Art. 12 de l\u2019instruction AMF n\u00b02005-11)&nbsp;: <a href=\"https:\/\/www.nicox.com\/assets\/files\/pr2013120500fr.pdf\">Emission par Nicox de 1.351.351 actions et de 1.500.000 bons d&rsquo;attribution d&rsquo;actions en r\u00e9mun\u00e9ration de l&rsquo;apport de la totalit\u00e9 du capital de la soci\u00e9t\u00e9 Eupharmed<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Nicox S.A. (NYSE Euronext Paris : COX) annonce aujourd\u2019hui la r\u00e9alisation d\u00e9finitive de l\u2019acquisition de 100% du capital d\u2019Eupharmed, soci\u00e9t\u00e9 pharmaceutique italienne priv\u00e9e sp\u00e9cialis\u00e9e en ophtalmologie. Cette acquisition s\u2019inscrit dans la strat\u00e9gie de Nicox visant \u00e0 \u00e9tablir une infrastructure commerciale dans les cinq principaux march\u00e9s europ\u00e9ens et aux Etats-Unis et apporte \u00e0 Nicox une plate-forme [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[32,16],"tags":[],"class_list":["post-6961","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-media"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nicox finalise l\u2019acquisition d\u2019Eupharmed - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/nicox-finalise-lacquisition-deupharmed\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nicox finalise l\u2019acquisition d\u2019Eupharmed - Nicox\" \/>\n<meta property=\"og:description\" content=\"Nicox S.A. (NYSE Euronext Paris : COX) annonce aujourd\u2019hui la r\u00e9alisation d\u00e9finitive de l\u2019acquisition de 100% du capital d\u2019Eupharmed, soci\u00e9t\u00e9 pharmaceutique italienne priv\u00e9e sp\u00e9cialis\u00e9e en ophtalmologie. Cette acquisition s\u2019inscrit dans la strat\u00e9gie de Nicox visant \u00e0 \u00e9tablir une infrastructure commerciale dans les cinq principaux march\u00e9s europ\u00e9ens et aux Etats-Unis et apporte \u00e0 Nicox une plate-forme [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/nicox-finalise-lacquisition-deupharmed\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:published_time\" content=\"1970-01-01T00:00:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-finalise-lacquisition-deupharmed\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-finalise-lacquisition-deupharmed\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Nicox finalise l\u2019acquisition d\u2019Eupharmed\",\"datePublished\":\"1970-01-01T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-finalise-lacquisition-deupharmed\\\/\"},\"wordCount\":165,\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\",\"Actualit\u00e9s et M\u00e9dia\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-finalise-lacquisition-deupharmed\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-finalise-lacquisition-deupharmed\\\/\",\"name\":\"Nicox finalise l\u2019acquisition d\u2019Eupharmed - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"1970-01-01T00:00:00+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-finalise-lacquisition-deupharmed\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nicox finalise l\u2019acquisition d\u2019Eupharmed - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/nicox-finalise-lacquisition-deupharmed\/","og_locale":"fr_FR","og_type":"article","og_title":"Nicox finalise l\u2019acquisition d\u2019Eupharmed - Nicox","og_description":"Nicox S.A. (NYSE Euronext Paris : COX) annonce aujourd\u2019hui la r\u00e9alisation d\u00e9finitive de l\u2019acquisition de 100% du capital d\u2019Eupharmed, soci\u00e9t\u00e9 pharmaceutique italienne priv\u00e9e sp\u00e9cialis\u00e9e en ophtalmologie. Cette acquisition s\u2019inscrit dans la strat\u00e9gie de Nicox visant \u00e0 \u00e9tablir une infrastructure commerciale dans les cinq principaux march\u00e9s europ\u00e9ens et aux Etats-Unis et apporte \u00e0 Nicox une plate-forme [&hellip;]","og_url":"https:\/\/www.nicox.com\/fr\/nicox-finalise-lacquisition-deupharmed\/","og_site_name":"Nicox","article_published_time":"1970-01-01T00:00:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.nicox.com\/fr\/nicox-finalise-lacquisition-deupharmed\/#article","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-finalise-lacquisition-deupharmed\/"},"author":{"name":"","@id":""},"headline":"Nicox finalise l\u2019acquisition d\u2019Eupharmed","datePublished":"1970-01-01T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-finalise-lacquisition-deupharmed\/"},"wordCount":165,"publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"articleSection":["Actualit\u00e9s","Actualit\u00e9s et M\u00e9dia"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/nicox-finalise-lacquisition-deupharmed\/","url":"https:\/\/www.nicox.com\/fr\/nicox-finalise-lacquisition-deupharmed\/","name":"Nicox finalise l\u2019acquisition d\u2019Eupharmed - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"1970-01-01T00:00:00+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/nicox-finalise-lacquisition-deupharmed\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/6961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=6961"}],"version-history":[{"count":0,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/6961\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=6961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/categories?post=6961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/tags?post=6961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}